Response to correspondence from Lichtenstein and Granet Re: Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis.
作者信息
Friedlaender Mitchell H, Protzko Eugene
机构信息
Division of Ophthalmology, Scripps Clinic, La Jolla, CA, 92037 USA.
出版信息
Clin Ophthalmol. 2008 Mar;2(1):242-4.
Abstract
摘要
相似文献
1
Response to correspondence from Lichtenstein and Granet Re: Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis.
Clin Ophthalmol. 2008 Mar;2(1):242-4.
2
Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis.
Patient Prefer Adherence. 2010 May 13;4:69-76. doi: 10.2147/ppa.s4203.
3
4
Fluoroquinolones compared to 1% azithromycin in DuraSite for bacterial conjunctivitis.
Clin Ophthalmol. 2008 Mar;2(1):241-2. doi: 10.2147/opth.s2819.
5
Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
Am J Ophthalmol. 2008 Jun;145(6):959-65. doi: 10.1016/j.ajo.2008.01.019. Epub 2008 Mar 28.
6
Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3425-9. doi: 10.1167/iovs.06-1413.
7
Ocular pharmacokinetics of AzaSite Xtra-2% azithromycin formulated in a DuraSite delivery system.
Curr Eye Res. 2009 Jun;34(6):485-91. doi: 10.1080/02713680902919532.
8
An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin.
Am J Ophthalmol. 2010 Oct;150(4):498-504.e1. doi: 10.1016/j.ajo.2010.05.006. Epub 2010 Aug 3.
9
The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment.
Adv Ther. 2008 Mar;25(3):208-17. doi: 10.1007/s12325-008-0034-x.
10
[Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
Klin Oczna. 2009;111(1-3):46-9.
引用本文的文献
1
Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis.
Patient Prefer Adherence. 2010 May 13;4:69-76. doi: 10.2147/ppa.s4203.
本文引用的文献
1
Improving adherence with antimicrobial therapy for respiratory tract infections: a discussion of directly observed therapy (DOT) and short-course therapies.
Am J Ther. 2004 Jul-Aug;11 Suppl 1:S18-21. doi: 10.1097/01.mjt.0000129050.13889.73.
2
An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite.
Clin Ophthalmol. 2007 Dec;1(4):519-25.
3
Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.
Clin Ophthalmol. 2007 Mar;1(1):3-10.
4
The increasing problem of antibiotic resistance.
J Cataract Refract Surg. 2007 Nov;33(11):1831-2. doi: 10.1016/j.jcrs.2007.09.005.
5
Fourth-generation fluoroquinolone-resistant bacterial keratitis.
J Cataract Refract Surg. 2007 Aug;33(8):1488-9. doi: 10.1016/j.jcrs.2007.04.015.
6
In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.
Arch Ophthalmol. 2006 Apr;124(4):479-83. doi: 10.1001/archopht.124.4.479.
7
A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Eur J Ophthalmol. 2005 Sep-Oct;15(5):541-9.
8
A systematic review and meta-analysis of misuse of antibiotic therapies in the community.
Int J Antimicrob Agents. 2005 Aug;26(2):106-13. doi: 10.1016/j.ijantimicag.2005.04.017.
9
Part I. Patient administration of eyedrops: interview.
Ann Ophthalmol. 1982 Aug;14(8):775-9.
Zotero 插件